Parabilis Medicines annual free cash flow
2024
2025
Parabilis Medicines Free Cash Flow (FCF) History (PBLS)
Parabilis Medicines reported $2.2M in free cash flow for fiscal 2025, an increase of 78.83% from the previous fiscal year.
View full Parabilis Medicines company overviewParabilis Medicines free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.2M | $968,000 | +78.83% | — |
| 2024 | 2024-12-31 | $1.2M | — | — | — |
Parabilis Medicines quarterly free cash flow
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$54.0M | $11.9M | — | −36516.22% |
| Q1 2026 | 2026-03-31 | $237,000 | −$343,000 | −59.14% | — |
| Q2 2025 | 2025-06-30 | −$65.9M | — | — | — |
| Q1 2025 | 2025-03-31 | $580,000 | — | — | — |
Parabilis Medicines free cash flow growth trends
Parabilis Medicines's latest reported quarter, Q2 2026, generated −$54.0M in free cash flow, an increase of $11.9M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Parabilis Medicines source filings ↗Community posts
Parabilis advances desmoid-tumor program after updated response data
Parabilis Medicines ($PBLS) reported a 72.2% response rate for investigational zolucatetide in a 32-week analysis of desmoid-tumor patients who started at doses of at least 450 milligrams. That figure represents 13 responses among 18 evalua ...
